Active Ingredient History
Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is indicated for the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women. It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anxiety Disorders (approved 2004)
Acute Pain (Phase 4)
Aged (Phase 4)
Alcoholism (Phase 2)
Amphetamine-Related Disorders (Phase 1)
Analgesics, Opioid (Phase 2)
Anesthesia (Phase 4)
Anticoagulants (Phase 1)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Arthroplasty, Replacement, Knee (Phase 4)
Back Pain (Phase 4)
Bariatric Surgery (Phase 3)
Bereavement (Phase 4)
Bipolar Disorder (Phase 4)
Brain Injuries, Traumatic (Phase 2)
Breast Neoplasms (Phase 3)
Bulimia (Phase 4)
Burning Mouth Syndrome (Phase 3)
Chronic Pain (Phase 4)
Cocaine-Related Disorders (Phase 1)
Cognition (Phase 3)
Cognitive Dysfunction (Phase 4)
Colorectal Neoplasms (Phase 2/Phase 3)
Cough (Phase 2)
Delirium (Phase 1/Phase 2)
Dementia (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 3)
Diabetes Mellitus (Phase 2/Phase 3)
Diabetic Neuropathies (Phase 4)
Drug Interactions (Phase 1)
Dysthymic Disorder (Phase 4)
Fatigue Syndrome, Chronic (Phase 2/Phase 3)
Fibromyalgia (Phase 4)
Fractures, Bone (Phase 4)
Gastrointestinal Microbiome (Phase 1)
Gulf War (Phase 2)
Gynecologic Surgical Procedures (Phase 4)
Headache (Phase 4)
Healthy Volunteers (Phase 4)
Hearing Loss (Phase 4)
HIV Infections (Phase 3)
Hyperalgesia (Phase 1)
Infertility, Male (Phase 4)
Intervertebral Disc Degeneration (Phase 4)
Irritable Bowel Syndrome (Phase 4)
Joint Diseases (Phase 4)
Knee Injuries (Phase 3)
Laparoscopy (Phase 4)
Low Back Pain (Phase 4)
Lung Diseases, Interstitial (Phase 2)
Lymphoma (Phase 2)
Menopause (Phase 4)
Methamphetamine (Phase 1)
Migraine Disorders (Phase 4)
Mood Disorders (Phase 1)
Multiple Sclerosis (Phase 3)
Musculoskeletal Diseases (Phase 3)
Musculoskeletal Pain (Phase 2)
Narcotics (Phase 2)
Neoplasms (Phase 4)
Neuralgia (Phase 4)
Neuralgia, Postherpetic (Phase 4)
Obsessive-Compulsive Disorder (Phase 4)
Opioid-Related Disorders (Phase 2)
Osteoarthritis (Phase 4)
Osteoarthritis, Knee (Phase 4)
Pain (Phase 4)
Pain, Postoperative (Phase 4)
Panic Disorder (Phase 4)
Parkinson Disease (Phase 4)
Peripheral Nervous System Diseases (Phase 3)
Pharmacokinetics (Phase 2)
Polyradiculoneuropathy (Phase 4)
Postoperative Complications (Phase 2/Phase 3)
Prostatic Neoplasms (Phase 3)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Renal Dialysis (Phase 4)
Schizophrenia (Phase 4)
Soft Tissue Injuries (Phase 4)
Sphincter of Oddi Dysfunction (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Early Phase 1)
Substance-Related Disorders (Phase 1)
Therapeutic Equivalency (Phase 1)
Urinary Incontinence (Phase 3)
Urinary Incontinence, Stress (Phase 4)
Vaccines (Phase 4)
Vasomotor System (Phase 4)
Virus Diseases (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
